Randomized phase II trial of gemcitabine plus weekly versus three-weekly paclitaxel in previously untreated advanced non-small-cell lung cancer.

C P Belani; S Dakhil; D M Waterhouse; C E Desch; D K Rooney; R H Clark; M J Monberg; Z Ye; C K Obasaju

doi:10.1093/annonc/mdl344

Randomized phase II trial of gemcitabine plus weekly versus three-weekly paclitaxel in previously untreated advanced non-small-cell lung cancer.

Identifier:nobleid.org/w1/20260515/AD09FC47

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/AD09FC47.svg?ark=w1%2F20260515%2FAD09FC47)](https://nobleid.org/work/w1/20260515/AD09FC47)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Randomized phase II trial of gemcitabine plus weekly versus three-weekly paclitaxel in previously untreated advanced non-small-cell lung cancer.

Identifier:nobleid.org/w1/20260515/AD09FC47

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/AD09FC47.svg?ark=w1%2F20260515%2FAD09FC47)](https://nobleid.org/work/w1/20260515/AD09FC47)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work